Health Catalyst Inc

Health Catalyst, Inc. engages in the provision of data and analytics technology and services to healthcare organizations. It operates through the Technology, and Professional Services segments. The Technology segment includes its data platform, analytics applications, and support services. The Professional Services segment combines analytics, implementation, strategic advisory, outsource, and improvement services to deliver expertise to its customers. The company was founded by Steven C. Barlow and Thomas D. Burton in 2008 and is headquartered in South Jordan, UT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Health Catalyst Inc reports solid 2022 performance and eyes margin growth opportunities

Health Catalyst Inc delivered strong financial performance in 2022, with revenue growth, improved EBITDA, and a positive outlook for 2023. The company's focus on client relationships, tech-enabled services, and margin improvement positions it well for future success. Challenges such as long sales cycles and migration costs are being managed strategically to drive growth.

Health Catalyst beats Q1 revenue targets, eyes tech-enabled growth

Health Catalyst's Q1 2023 performance showed revenue growth and operational efficiency, with a focus on recurring revenue and client relationships.
While facing challenges in the health system market and revenue lumpiness, the company aims for growth through tech-enabled services and cost-saving strategies.
Opportunities lie in expanding into the ambulatory space, offering modular solutions, and investing in tech capabilities for long-term differentiation and client value.
Overall, Health Catalyst remains cautious about expansion, prioritizing being a differentiated long-term partner to effectively deliver for clients.

Health Catalyst beats Q2 expectations, eyes growth in managed services

Health Catalyst's Q2 performance exceeded expectations, with raised guidance for 2023.
Focus on tech-enabled managed services and long-term client relationships driving growth.
Challenges include longer sales cycles and improving gross margins in contracts.
Opportunities lie in margin improvement, summit impact on bookings, and clinic operations.

Health Catalyst Inc beats Q3 revenue, eyes strong Q4 bookings

Health Catalyst Inc (HCAT) exceeded revenue expectations in Q3 2023 and raised full-year guidance, with strong bookings performance.
The company is focusing on optimizing costs, anticipating a large bookings quarter in Q4 2023.
Recognized for team member engagement and client success stories, with a healthy cash position.
Anticipating growth opportunities in professional services and tech-enabled managed services contracts.

Health Catalyst exceeds Q4 revenue targets, eyes sustainable growth

Health Catalyst Inc's Q4 2023 earnings call highlighted strong financial performance, exceeding revenue and EBITDA guidance, with a focus on client growth and retention.
The company's strategic objectives include migrating clients to a next-gen data platform, balancing growth between tech and services, and driving profitability through operational efficiency.
While facing challenges in client migration and balancing growth, Health Catalyst is well-positioned to capitalize on opportunities like the next-gen platform rollout and cross-selling efforts.
Overall, Health Catalyst's performance, strengths, challenges, and opportunities indicate a strategic focus on sustainable growth, profitability, and enhancing client relationships.

Health Catalyst surpasses Q1 expectations, eyes tech-driven growth

Health Catalyst demonstrated financial resilience and client-centric approach in Q1 2024.
Strategic focus on technology and services to drive growth and avoid limitations.
Opportunities in adjacent markets and client engagement for sustained expansion.
Challenges include managing R&D expenses and potential disruptions from external factors.

Health Catalyst surpasses Q2 revenue targets, eyes growth opportunities

Health Catalyst's Q2 2024 performance exceeded expectations, showcasing strong revenue and margin metrics.
The company's strategic strengths lie in client recognition, acquisitions, platform migration progress, and growth outlook.
Challenges include client retention, revenue growth, margin optimization, and disciplined capital deployment.
Opportunities for Health Catalyst include leveraging financial strength, cross-selling, technology focus, and Ignite platform benefits.

Health Catalyst exceeds Q3 expectations, eyes growth through strategic initiatives

Health Catalyst Inc's Q3 2024 earnings call showcased strong financial performance, positive outlook, and strategic initiatives for growth.
The company's focus on client relationships, market demand, and acquisitions positions it well for future success and industry leadership.
While challenges like margin expansion and competition exist, Health Catalyst Inc's strengths and opportunities indicate a promising trajectory.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Health Catalyst, Inc. engages in the provision of data and analytics technology and services to healthcare organizations. It operates through the Technology and Professional Services segments. The Technology segment includes its data platform, analytics applications, and support services. The Professional Services segment combines analytics, implementation, strategic advisory, outsource, and improvement services to deliver expertise to its customers. The company was founded by Steven C. Barlow and Thomas D. Burton in 2008 and is headquartered in South Jordan, UT.

Health Catalyst (HCAT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Why Health Catalyst (HCAT) Might be Well Poised for a Surge

The average of price targets set by Wall Street analysts indicates a potential upside of 75.2% in Health Catalyst (HCAT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts See a 75.19% Upside in Health Catalyst (HCAT): Can the Stock Really Move This High?

SALT LAKE CITY , May 21, 2024 /PRNewswire/ -- Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced the launch of Health Catalyst Ignite® , a next-generation healthcare data and analytics ecosystem that combines best-in-class technologies, healthcare-specific data models, self-service tools, and industry expertise in one modern environment. Today's health systems face significant challenges in navigating a path to clinical, operational, and financial success.

Health Catalyst Unveils Next-Generation Data and Analytics Ecosystem Built for Healthcare, Health Catalyst Ignite®

Health Catalyst, Inc. (NASDAQ:HCAT ) Q1 2024 Earnings Conference Call May 9, 2024 5:00 PM ET Company Participants Jack Knight - VP, Investor Relations Daniel Burton - CEO & Director Jason Alger - CFO Conference Call Participants Jared Haase - William Blair & Co. Elizabeth Anderson - Evercore ISI Anna Kruszenski - Barclays Capital John Ransom - Raymond James Daniel Grosslight - Citigroup Jenny Shen - BTIG Mitchell Ostrovsky - Guggenheim Securities Stan Berenshteyn - Wells Fargo & Co. Operator Good afternoon, everyone, and welcome to the Health Catalyst First Quarter 2024 Earnings Conference Call. [Operator Instructions].

Health Catalyst, Inc. (HCAT) Q1 2024 Earnings Call Transcript

The headline numbers for Health Catalyst (HCAT) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Health Catalyst (HCAT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Health Catalyst (HCAT) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to earnings of $0.05 per share a year ago.

Health Catalyst (HCAT) Q1 Earnings Beat Estimates

SALT LAKE CITY, May 09, 2024 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported financial results for the quarter ended March 31, 2024.

Health Catalyst Reports First Quarter 2024 Results

Get a deeper insight into the potential performance of Health Catalyst (HCAT) for the quarter ended March 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Health Catalyst (HCAT) Q1 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

SALT LAKE CITY, April 24, 2024 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, will release its first quarter 2024 operating results on Thursday, May 9, 2024, after market close. In conjunction, the company will host a conference call to review the results at 5 p.m. E.T. on the same day.

Health Catalyst to Announce First Quarter 2024 Operating Results and Host Conference Call on Thursday, May 9, 2024

Health Catalyst (HCAT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Down -24.71% in 4 Weeks, Here's Why You Should You Buy the Dip in Health Catalyst (HCAT)

The mean of analysts' price targets for Health Catalyst (HCAT) points to a 53.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Think Health Catalyst (HCAT) Could Surge 53.65%: Read This Before Placing a Bet

Inspire Medical Systems Inc

Talkspace

A few Zacks Medical Info Systems industry stocks like Inspire Medical Systems (INSP), Talkspace (TALK) and Health Catalyst (HCAT) are expected to gain from the new normal trends.

3 Medical Info Systems Stocks to Buy as Industry Improves

Health Catalyst reported strong Q4 results, meeting guidance and showing growth in technology and professional services revenue. The drop in HCAT's share price presents a buying opportunity, as the company's growth initiatives, such as its TEMS offering and next-gen data platform, are expected to drive growth and margin expansion. HCAT's long-term guidance of exceeding $100 million in EBITDA by FY28 is achievable, and its valuation should improve as it demonstrates execution and margin expansion.

Health Catalyst: Achieving FY28 Long-Term Guidance Is Possible

SALT LAKE CITY , Feb. 27, 2024 /PRNewswire/ -- Today, Health Catalyst announced the winner of the 2024 Flywheel Award. The award recognizes healthcare organizations that have showcased outstanding results in measurable, impactful improvements.

Health Catalyst Names UnityPoint Health Winner of the 2024 Flywheel Award

The heavy selling pressure might have exhausted for Health Catalyst (HCAT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

After Plunging -24.47% in 4 Weeks, Here's Why the Trend Might Reverse for Health Catalyst (HCAT)

Health Catalyst, Inc. (HCAT) Q4 2023 Earnings Call Transcript

Although the revenue and EPS for Health Catalyst (HCAT) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Compared to Estimates, Health Catalyst (HCAT) Q4 Earnings: A Look at Key Metrics

Health Catalyst (HCAT) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.01 per share. This compares to loss of $0.05 per share a year ago.

Health Catalyst (HCAT) Q4 Earnings and Revenues Beat Estimates

SOUTH JORDAN, Utah., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported financial results for the quarter and year ended December 31, 2023.

Health Catalyst Reports Fourth Quarter and Year End 2023 Results

SALT LAKE CITY , Feb. 21, 2024 /PRNewswire/ -- Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced that the Able Health Registry has received Quality Payment Program (QPP) Qualified Registry approval for the 2024 performance year by the Centers for Medicare and Medicaid Services (CMS). According to CMS, the QPP program "aims to improve the quality and safety of care for all individuals and to reduce the administrative burden on clinicians, allowing more time to focus on person-centered care and improving health outcomes.

Health Catalyst's Able Health Registry Receives CMS's QPP Qualified Registry Approval for 2024

SALT LAKE CITY , Feb. 21, 2024 /PRNewswire/ -- Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced MeasureAble™ has achieved Office of the National Coordinator for Health Information Technology (ONC-Health IT) 2015 Edition Health IT certification via Drummond Group LLC, an Authorized Certification Body (ACB). This approval designates that eligible providers and hospitals may use MeasureAble to meet requirements for various quality reporting programs that involve the use of certified electronic health records (EHR) technology to calculate and report quality measures.

Health Catalyst's MeasureAble™ Earns ONC Health IT Certification

Beyond analysts' top -and-bottom-line estimates for Health Catalyst (HCAT), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.

Health Catalyst (HCAT) Q4 Earnings Preview: What You Should Know Beyond the Headline Estimates

SALT LAKE CITY, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, will release its fourth quarter and full year 2023 operating results on Thursday, February 22, 2024, after market close. In conjunction, the company will host a conference call to review the results at 5 p.m. E.T. on the same day.

Health Catalyst to Announce Fourth Quarter and Full Year 2023 Operating Results and Host Conference Call on Thursday, February 22, 2024

SALT LAKE CITY , Feb. 7, 2024 /PRNewswire/ -- Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced that VitalCDM, Vitalware by Health Catalyst's flagship hospital chargemaster solution, ranked number one in the Revenue Cycle - Chargemaster Management category of the "2024 Best in KLAS: Software & Services."  "Each day, our team members dedicate themselves to delivering world-class service and product excellence in support of our clients and their financial and regulatory needs.

Vitalware by Health Catalyst Earns Best in KLAS Achievement in Chargemaster Management

The consensus price target hints at a 29% upside potential for Health Catalyst (HCAT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

News for Health Catalyst Inc Stock (HCAT)